vs
Side-by-side financial comparison of Local Bounti Corporation (LOCL) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Local Bounti Corporation is the larger business by last-quarter revenue ($12.5M vs $9.3M, roughly 1.3× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -69.8%, a 70.4% gap on every dollar of revenue. On growth, Local Bounti Corporation posted the faster year-over-year revenue change (23.7% vs -3.0%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-3.6M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs 17.3%).
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
LOCL vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $9.3M |
| Net Profit | $-8.7M | $58.0K |
| Gross Margin | 12.2% | 61.8% |
| Operating Margin | -106.1% | 5.3% |
| Net Margin | -69.8% | 0.6% |
| Revenue YoY | 23.7% | -3.0% |
| Net Profit YoY | 76.0% | 101.3% |
| EPS (diluted) | $1.52 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $9.3M | ||
| Q3 25 | $12.2M | $6.9M | ||
| Q2 25 | $12.1M | $7.7M | ||
| Q1 25 | $11.6M | $6.8M | ||
| Q4 24 | $10.1M | $9.6M | ||
| Q3 24 | $10.2M | $8.8M | ||
| Q2 24 | $9.4M | $8.4M | ||
| Q1 24 | $8.4M | $6.8M |
| Q4 25 | $-8.7M | $58.0K | ||
| Q3 25 | $-26.4M | $-1.6M | ||
| Q2 25 | $-21.6M | $-2.6M | ||
| Q1 25 | $-37.7M | $-2.1M | ||
| Q4 24 | $-36.3M | $-4.6M | ||
| Q3 24 | $-34.3M | $-2.1M | ||
| Q2 24 | $-25.3M | $-91.0K | ||
| Q1 24 | $-24.1M | $-3.4M |
| Q4 25 | 12.2% | 61.8% | ||
| Q3 25 | 11.5% | 60.4% | ||
| Q2 25 | 12.2% | 56.2% | ||
| Q1 25 | 12.6% | 53.5% | ||
| Q4 24 | 5.4% | 61.4% | ||
| Q3 24 | 13.8% | 60.1% | ||
| Q2 24 | 14.3% | 59.0% | ||
| Q1 24 | 9.4% | 45.6% |
| Q4 25 | -106.1% | 5.3% | ||
| Q3 25 | -149.4% | -16.9% | ||
| Q2 25 | -127.7% | -30.1% | ||
| Q1 25 | -135.6% | -25.0% | ||
| Q4 24 | -166.6% | -44.7% | ||
| Q3 24 | -176.0% | -18.2% | ||
| Q2 24 | -146.8% | -5.7% | ||
| Q1 24 | -122.9% | -42.7% |
| Q4 25 | -69.8% | 0.6% | ||
| Q3 25 | -216.6% | -23.4% | ||
| Q2 25 | -178.3% | -33.6% | ||
| Q1 25 | -324.6% | -31.2% | ||
| Q4 24 | -360.1% | -47.6% | ||
| Q3 24 | -335.2% | -23.6% | ||
| Q2 24 | -267.6% | -1.1% | ||
| Q1 24 | -286.9% | -49.8% |
| Q4 25 | $1.52 | $0.14 | ||
| Q3 25 | $-1.18 | $-0.36 | ||
| Q2 25 | $-1.63 | $-0.62 | ||
| Q1 25 | $-4.32 | $-0.51 | ||
| Q4 24 | $-4.24 | $-2.01 | ||
| Q3 24 | $-4.01 | $-0.51 | ||
| Q2 24 | $-3.00 | $-0.03 | ||
| Q1 24 | $-2.89 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $7.9M |
| Total DebtLower is stronger | $483.1M | $15.3M |
| Stockholders' EquityBook value | $-166.2M | $2.9M |
| Total Assets | $410.5M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.2M | $7.9M | ||
| Q3 25 | $6.2M | $7.1M | ||
| Q2 25 | $5.3M | $6.0M | ||
| Q1 25 | $18.0M | $6.5M | ||
| Q4 24 | $937.0K | $7.3M | ||
| Q3 24 | $317.0K | $7.1M | ||
| Q2 24 | $9.7M | $5.5M | ||
| Q1 24 | $8.2M | $5.2M |
| Q4 25 | $483.1M | $15.3M | ||
| Q3 25 | $484.9M | $15.3M | ||
| Q2 25 | $478.3M | $15.0M | ||
| Q1 25 | $480.0M | $15.0M | ||
| Q4 24 | $436.8M | $15.0M | ||
| Q3 24 | $398.4M | $15.0M | ||
| Q2 24 | $374.0M | $15.0M | ||
| Q1 24 | $329.8M | $15.0M |
| Q4 25 | $-166.2M | $2.9M | ||
| Q3 25 | $-158.1M | $1.3M | ||
| Q2 25 | $-132.7M | $532.0K | ||
| Q1 25 | $-134.5M | $3.0M | ||
| Q4 24 | $-100.5M | $5.0M | ||
| Q3 24 | $-65.6M | $9.4M | ||
| Q2 24 | $-32.8M | $9.5M | ||
| Q1 24 | $-9.4M | $9.4M |
| Q4 25 | $410.5M | $30.5M | ||
| Q3 25 | $417.8M | $30.7M | ||
| Q2 25 | $426.8M | $29.5M | ||
| Q1 25 | $447.2M | $33.0M | ||
| Q4 24 | $428.0M | $34.9M | ||
| Q3 24 | $430.8M | $39.4M | ||
| Q2 24 | $438.1M | $38.8M | ||
| Q1 24 | $413.4M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.1M | $-239.0K |
| Free Cash FlowOCF − Capex | $-3.6M | $-551.0K |
| FCF MarginFCF / Revenue | -29.1% | -5.9% |
| Capex IntensityCapex / Revenue | 3.9% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-42.9M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.1M | $-239.0K | ||
| Q3 25 | $-8.9M | $-64.0K | ||
| Q2 25 | $-8.7M | $-1.9M | ||
| Q1 25 | $-9.6M | $-550.0K | ||
| Q4 24 | $1.2M | $703.0K | ||
| Q3 24 | $-17.2M | $-302.0K | ||
| Q2 24 | $-4.0M | $591.0K | ||
| Q1 24 | $-7.1M | $-804.0K |
| Q4 25 | $-3.6M | $-551.0K | ||
| Q3 25 | $-10.1M | $-1.1M | ||
| Q2 25 | $-14.6M | $-2.0M | ||
| Q1 25 | $-14.5M | $-749.0K | ||
| Q4 24 | $-8.6M | $199.0K | ||
| Q3 24 | $-30.0M | $-364.0K | ||
| Q2 24 | $-28.8M | $246.0K | ||
| Q1 24 | $-42.1M | $-1.5M |
| Q4 25 | -29.1% | -5.9% | ||
| Q3 25 | -82.8% | -15.6% | ||
| Q2 25 | -121.0% | -26.1% | ||
| Q1 25 | -125.1% | -11.0% | ||
| Q4 24 | -85.3% | 2.1% | ||
| Q3 24 | -293.1% | -4.1% | ||
| Q2 24 | -305.4% | 2.9% | ||
| Q1 24 | -501.8% | -22.6% |
| Q4 25 | 3.9% | 3.4% | ||
| Q3 25 | 9.7% | 14.7% | ||
| Q2 25 | 48.9% | 0.8% | ||
| Q1 25 | 42.8% | 2.9% | ||
| Q4 24 | 97.6% | 5.3% | ||
| Q3 24 | 125.0% | 0.7% | ||
| Q2 24 | 263.0% | 4.1% | ||
| Q1 24 | 417.3% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOCL
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
